ECSP19035171A - Formas cristalinas de un inhibidor de magl - Google Patents
Formas cristalinas de un inhibidor de maglInfo
- Publication number
- ECSP19035171A ECSP19035171A ECSENADI201935171A ECDI201935171A ECSP19035171A EC SP19035171 A ECSP19035171 A EC SP19035171A EC SENADI201935171 A ECSENADI201935171 A EC SENADI201935171A EC DI201935171 A ECDI201935171 A EC DI201935171A EC SP19035171 A ECSP19035171 A EC SP19035171A
- Authority
- EC
- Ecuador
- Prior art keywords
- crystal forms
- magl inhibitor
- magl
- inhibitor
- hexafluoropropan
- Prior art date
Links
- 229940122357 Monoacylglycerol lipase inhibitor Drugs 0.000 title abstract 2
- 239000013078 crystal Substances 0.000 title 1
- -1 1,1,1,3,3,3-hexafluoropropan-2-yl Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/205—Radicals derived from carbonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662423126P | 2016-11-16 | 2016-11-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP19035171A true ECSP19035171A (es) | 2019-05-31 |
Family
ID=62145805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI201935171A ECSP19035171A (es) | 2016-11-16 | 2019-05-16 | Formas cristalinas de un inhibidor de magl |
Country Status (38)
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2982694T3 (es) | 2012-01-06 | 2024-10-17 | H Lundbeck As | Compuestos de carbamato para su uso en tratamiento |
| BR112017024253A2 (pt) | 2015-05-11 | 2018-07-24 | Abide Therapeutics Inc | métodos de tratamento de inflamação ou dor neuropática. |
| WO2018053447A1 (en) | 2016-09-19 | 2018-03-22 | Abide Therapeutics, Inc. | Piperazine carbamates and methods of making and using same |
| HUE056973T2 (hu) | 2016-11-16 | 2022-04-28 | H Lundbeck As | MAGL inhibitor kristályos formája |
| CA3043609A1 (en) | 2016-11-16 | 2018-05-24 | Abide Therapeutics, Inc. | Pharmaceutical formulations |
| JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| US10927105B1 (en) | 2017-05-23 | 2021-02-23 | Lundbeck La Jolla Research Center, Inc. | Pyrazole MAGL inhibitors |
| JOP20190262B1 (ar) | 2017-05-23 | 2023-09-17 | H Lundbeck As | مثبطات بيرازول magl |
| EP3675847B1 (en) | 2017-08-29 | 2023-07-12 | H. Lundbeck A/S | Spirocycle compounds and methods of making and using same |
| JOP20200276A1 (ar) * | 2018-05-15 | 2020-11-02 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| US20210309669A1 (en) * | 2018-07-19 | 2021-10-07 | Pfizer Inc. | Heterocyclic Spiro Compounds As MAGL Inhibitors |
| WO2020035424A1 (en) | 2018-08-13 | 2020-02-20 | F. Hoffmann-La Roche Ag | New heterocyclic compounds as monoacylglycerol lipase inhibitors |
| MX2021008865A (es) * | 2019-01-25 | 2021-10-26 | H Lundbeck As | Inhibidores de magl para usarse para tratar enfermedades antecedentes. |
| EP4058431A4 (en) * | 2019-11-15 | 2023-11-15 | H. Lundbeck A/S | Crystalline forms of a magl inhibitor |
| MX2022013224A (es) | 2020-04-21 | 2022-11-14 | H Lundbeck As | Sintesis de un inhibidor de la monoacilglicerol lipasa. |
| WO2023092079A1 (en) * | 2021-11-19 | 2023-05-25 | Bryant Cynthia W | Use of cannabinoid compounds to treat gastrointestinal disorders |
| KR20240128870A (ko) | 2021-12-29 | 2024-08-27 | 싸이 테라퓨틱스, 인크. | 모노아실글리세롤 리파아제(magl) 억제 |
| AU2023264787A1 (en) | 2022-05-04 | 2024-10-31 | H. Lundbeck A/S | Crystalline form of 1,1,1,3,3,3-hexafluoropropan-2-yl (s)-1-(pyridazin-3-ylcarbamoyl)-6 azaspiro[2.5]octane-6-carboxylate as monoacylglycerol lipase inhibitor. |
| CN117665187B (zh) * | 2023-11-23 | 2024-08-16 | 宁波大红鹰药业股份有限公司 | 一种舒林酸中间体杂质的测定方法 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
| US4624848A (en) | 1984-05-10 | 1986-11-25 | Ciba-Geigy Corporation | Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use |
| US4968509A (en) | 1987-07-27 | 1990-11-06 | Mcneilab, Inc. | Oral sustained release acetaminophen formulation and process |
| IL92966A (en) | 1989-01-12 | 1995-07-31 | Pfizer | Dispensing devices powered by hydrogel |
| WO1992018106A1 (fr) | 1991-04-16 | 1992-10-29 | Nippon Shinyaku Co., Ltd. | Procede de production d'une dispersion solide |
| WO1993009785A1 (en) | 1991-11-22 | 1993-05-27 | Procter & Gamble Pharmaceuticals, Inc. | Risedronate delayed-release compositions |
| US5461140A (en) | 1992-04-30 | 1995-10-24 | Pharmaceutical Delivery Systems | Bioerodible polymers for solid controlled release pharmaceutical compositions |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| ES2180548T3 (es) | 1992-10-16 | 2003-02-16 | Nippon Shinyaku Co Ltd | Metodo de obtencion de matrices de cera. |
| US5686105A (en) | 1993-10-19 | 1997-11-11 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
| KR19990014865A (ko) | 1995-05-17 | 1999-02-25 | 피터 이. 브래이브맨 | 소장에서의 소화 및 흡수를 증진시키기 위한, 지방산을 함유한조성물들 |
| US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| AU2001225816B2 (en) | 2000-12-18 | 2005-10-13 | Novartis Ag | Therapeutic combination of amlodipine and benazepril |
| US6465014B1 (en) | 2001-03-21 | 2002-10-15 | Isp Investments Inc. | pH-dependent sustained release, drug-delivery composition |
| MXPA04008073A (es) | 2002-02-20 | 2004-11-26 | Abbott Lab | Compuestos azabiciclicos fusionados que inhiben el receptor de subtipo 1 (vr1) del receptor de vainilloide. |
| US7074805B2 (en) | 2002-02-20 | 2006-07-11 | Abbott Laboratories | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
| BRPI0606187A2 (pt) | 2005-02-25 | 2009-06-09 | Hoffmann La Roche | comprimidos com capacidade de dispersão da substáncia do fármaco melhorada |
| NZ568700A (en) | 2005-11-28 | 2012-03-30 | Marinus Pharmaceuticals | Solid stabilized particulate formulations comprising ganaxolone |
| EP1938804A1 (en) | 2006-12-22 | 2008-07-02 | Novartis AG | Pharmaceutical formulation comprising neurokinin antagonist |
| FR2938341A1 (fr) | 2008-11-13 | 2010-05-14 | Galderma Res & Dev | Modulateurs de la monoglyceride lipase dans le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee |
| WO2010063802A1 (en) | 2008-12-05 | 2010-06-10 | Novartis Ag | 3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists |
| CN101530399B (zh) | 2009-04-15 | 2011-01-26 | 江苏中兴药业有限公司 | 一种水飞蓟宾固体自乳化片 |
| ES2982694T3 (es) * | 2012-01-06 | 2024-10-17 | H Lundbeck As | Compuestos de carbamato para su uso en tratamiento |
| CN104379578B (zh) | 2012-03-19 | 2017-06-09 | 阿比德治疗公司 | 氨基甲酸酯化合物及其制备和使用方法 |
| WO2013159095A1 (en) | 2012-04-20 | 2013-10-24 | Anderson Gaweco | Ror modulators and their uses |
| DK2914248T4 (da) | 2012-11-02 | 2024-01-02 | Vertex Pharma | Farmaceutiske sammensætninger til behandlingen af cftr medierede sygdomme |
| TW201446286A (zh) | 2013-01-31 | 2014-12-16 | Gilead Pharmasset Llc | 抗病毒化合物之固態分散調製劑 |
| US9551036B2 (en) | 2013-02-25 | 2017-01-24 | Whitehead Institute For Biomedical Research | Metabolic gene mesenchymal signatures and uses thereof |
| WO2015003002A1 (en) | 2013-07-03 | 2015-01-08 | Abide Therapeutics, Inc. | Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof |
| WO2015030854A1 (en) | 2013-08-27 | 2015-03-05 | Gilead Pharmasset Llc | Solid dispersion formulation of an antiviral compound |
| CN103893258B (zh) | 2013-12-05 | 2017-09-29 | 人福医药集团股份公司 | 含有广金钱草总黄酮的口服固体制剂及其应用 |
| WO2015164160A1 (en) * | 2014-04-21 | 2015-10-29 | Merck Sharp & Dohme Corp. | Pharmaceutical salts of an orexin receptor antagonist |
| WO2015179559A2 (en) | 2014-05-21 | 2015-11-26 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
| US9771341B2 (en) | 2015-03-18 | 2017-09-26 | Abide Therapeutics, Inc. | Piperazine carbamates and methods of making and using same |
| BR112017024253A2 (pt) | 2015-05-11 | 2018-07-24 | Abide Therapeutics Inc | métodos de tratamento de inflamação ou dor neuropática. |
| US10463753B2 (en) * | 2016-02-19 | 2019-11-05 | Lundbeck La Jolla Research Center, Inc. | Radiolabeled monoacylglycerol lipase occupancy probe |
| JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| JOP20190106A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| HUE056973T2 (hu) | 2016-11-16 | 2022-04-28 | H Lundbeck As | MAGL inhibitor kristályos formája |
| CA3043609A1 (en) | 2016-11-16 | 2018-05-24 | Abide Therapeutics, Inc. | Pharmaceutical formulations |
| JOP20190105A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
-
2017
- 2017-11-15 HU HUE17872429A patent/HUE056973T2/hu unknown
- 2017-11-15 EA EA201991086A patent/EA201991086A1/ru unknown
- 2017-11-15 ES ES21199077T patent/ES2966939T3/es active Active
- 2017-11-15 MX MX2019005767A patent/MX389459B/es unknown
- 2017-11-15 PL PL21199077.5T patent/PL3964503T3/pl unknown
- 2017-11-15 GE GEAP201715091A patent/GEP20237559B/en unknown
- 2017-11-15 EP EP17872429.0A patent/EP3541807B1/en active Active
- 2017-11-15 DK DK17872429.0T patent/DK3541807T3/da active
- 2017-11-15 MY MYPI2019002687A patent/MY199386A/en unknown
- 2017-11-15 SM SM20210675T patent/SMT202100675T1/it unknown
- 2017-11-15 BR BR112019010003A patent/BR112019010003A2/pt not_active Application Discontinuation
- 2017-11-15 JO JOP/2019/0109A patent/JOP20190109B1/ar active
- 2017-11-15 TN TNP/2019/000151A patent/TN2019000151A1/en unknown
- 2017-11-15 HU HUE21199077A patent/HUE064559T2/hu unknown
- 2017-11-15 WO PCT/US2017/061875 patent/WO2018093953A1/en not_active Ceased
- 2017-11-15 RS RS20231263A patent/RS65016B1/sr unknown
- 2017-11-15 HR HRP20211863TT patent/HRP20211863T1/hr unknown
- 2017-11-15 ES ES17872429T patent/ES2900016T3/es active Active
- 2017-11-15 CR CR20190242A patent/CR20190242A/es unknown
- 2017-11-15 MA MA58133A patent/MA58133B1/fr unknown
- 2017-11-15 CN CN201780083644.3A patent/CN110291083B/zh not_active Expired - Fee Related
- 2017-11-15 JP JP2019523672A patent/JP7042548B2/ja not_active Expired - Fee Related
- 2017-11-15 RS RS20211501A patent/RS62665B1/sr unknown
- 2017-11-15 SI SI201730987T patent/SI3541807T1/sl unknown
- 2017-11-15 PT PT178724290T patent/PT3541807T/pt unknown
- 2017-11-15 SM SM20230494T patent/SMT202300494T1/it unknown
- 2017-11-15 KR KR1020197017161A patent/KR102508739B1/ko active Active
- 2017-11-15 CN CN202210681321.7A patent/CN115093382A/zh active Pending
- 2017-11-15 PE PE2019001013A patent/PE20191239A1/es unknown
- 2017-11-15 EP EP21199077.5A patent/EP3964503B1/en active Active
- 2017-11-15 AU AU2017361257A patent/AU2017361257B2/en not_active Ceased
- 2017-11-15 PL PL17872429T patent/PL3541807T3/pl unknown
- 2017-11-15 LT LTEPPCT/US2017/061875T patent/LT3541807T/lt unknown
- 2017-11-15 US US16/349,142 patent/US11142517B2/en active Active
- 2017-11-15 CA CA3043610A patent/CA3043610A1/en active Pending
- 2017-11-15 UA UAA201905624A patent/UA124585C2/uk unknown
- 2017-11-15 MA MA46866A patent/MA46866B1/fr unknown
- 2017-11-15 HR HRP20231697TT patent/HRP20231697T1/hr unknown
-
2019
- 2019-05-12 IL IL266548A patent/IL266548A/en unknown
- 2019-05-14 PH PH12019501068A patent/PH12019501068A1/en unknown
- 2019-05-16 MX MX2022000249A patent/MX2022000249A/es unknown
- 2019-05-16 CO CONC2019/0005045A patent/CO2019005045A2/es unknown
- 2019-05-16 NI NI201900053A patent/NI201900053A/es unknown
- 2019-05-16 EC ECSENADI201935171A patent/ECSP19035171A/es unknown
- 2019-05-16 CL CL2019001340A patent/CL2019001340A1/es unknown
- 2019-05-16 DO DO2019000120A patent/DOP2019000120A/es unknown
- 2019-05-17 ZA ZA2019/03093A patent/ZA201903093B/en unknown
-
2021
- 2021-09-08 US US17/469,535 patent/US11993588B2/en active Active
- 2021-12-13 CY CY20211101092T patent/CY1124870T1/el unknown
-
2022
- 2022-03-08 JP JP2022035398A patent/JP7350117B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP19035171A (es) | Formas cristalinas de un inhibidor de magl | |
| CY1125214T1 (el) | Ενωσεις ν-((ετ)αρυλμεθυλ)-ετεροαρυλ-καρβοξαμιδιων ως αναστολεις καλλικρεϊνης πλασματος | |
| ECSP20001149A (es) | Compuestos antiproliferativos y métodos para utilizarlos | |
| CY1124088T1 (el) | Παραγωγα 2,4-θειαζολιδινεδιονης στη θεραπεια διαταραχων του κεντρικου νευρικου συστηματος | |
| CY2024024I1 (el) | Υδροχλωρικα αλατα ν-(κυανομεθυλ)-4-(2-(4- μορφολινοφαινυλαμινο)πυριμιδιν-4-υλ)βενζαμιδιου | |
| EA201991697A1 (ru) | Сульфоксиминовые ингибиторы гликозидазы | |
| EA201992300A1 (ru) | КРИСТАЛЛИЧЕСКАЯ ФОРМА 6-(ЦИКЛОПРОПАНКАРБОКСАМИДО)-4-((2-МЕТОКСИ-3-(1-МЕТИЛ-1H-1,2,4-ТРИАЗОЛ-3-ИЛ)ФЕНИЛ)АМИНО)-N-(МЕТИЛ-d3)ПИРИДАЗИН-3-КАРБОКСАМИДА | |
| AR111469A1 (es) | Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma | |
| EA202191051A1 (ru) | Ингибитор аврора-киназы a для применения для лечения нейробластомы | |
| IL278854A (en) | Treatment of multiple myeloma and the use of biomarkers for 4-(4-(4-(((2-(6,2-dioxopyridin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazine-1 -yl-3-fluorobenzonitrile | |
| EA201992259A1 (ru) | Замещенные n-(1,3,4-оксадиазол-2-ил)арилкарбоксамиды и их применение в качестве гербицидов | |
| MX2019015150A (es) | Composiciones antagonistas de nk-1 y métodos para su uso en el tratamiento de la depresión. | |
| CL2022002895A1 (es) | Síntesis de un inhibidor de la monoacilglicerol lipasa. | |
| MX2020011756A (es) | Compuesto farmaceutico, sales del mismo, formulaciones del mismo y metodos para hacer y usar el mismo. | |
| CL2019000377A1 (es) | Compuesto para uso en el tratamiento de hipotensión ortostática neurogénica. | |
| CO6680652A2 (es) | Usos terapéuticos de 1-[2-(2.4-dimetil-fenilsulfanil)fenil]piperazina | |
| AR104935A1 (es) | Formas cristalinas de un inhibidor de histona deacetilasa | |
| AR110998A1 (es) | Inhibidores de la tirosina cinasa de bruton | |
| EP3654966C0 (en) | AMORPHOUS DISPERSIONS OF EPIGALLOCATECHIN GALLATE | |
| CO2018000953A2 (es) | Asociación entre la 3 - [(3 - {[4- (4-morfolinilmetil) -1h-pirrol-2-il] metilen} -2-oxo-2,3-dihidro-1h-indol-5-il) metil ] -1,3-tiazolidina-2,4-diona y un inhibidor de la tyr quinasa del egfr | |
| MX370375B (es) | Cristal de derivado de azol-benceno. | |
| UA108342U (uk) | 7-н-бутил-8-n,n-діетиламіноетиламіно-3-метилксантину сукцинат, який виявляє діуретичну та аналгетичну дію | |
| HK40051930A (en) | Treating multiple myeloma and the use of biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1- oxoisoindolin-4-yl)oxy)methyl)benzyl) piperazin-1-yl)-3-fluorobenzonitrile | |
| UA136980U (uk) | 2-(5,7-БІС-ЕТИЛАМІНО[1,2,4]ТРИАЗОЛО[4,3-a][1,3,5]ТРИАЗИН-3-ІЛ-СУЛЬФАНІЛ)-N-(2,4-ДИМЕТОКСИФЕНІЛ)-АЦЕТАМІД, ЩО МАЄ ПРОТИЗАПАЛЬНУ ДІЮ | |
| UA127754U (uk) | Поліетергуанідингідрохлорид як бактерицидна речовина |